CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 56 enrolled
Drug / intervention
Gumarontinib Tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03466268
NCT03466268Phase 1Completed
CompareCT.gov

A Phase I Trial to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of SCC244 in Subjects With Advanced Solid Tumors

Haihe Biopharma Co., Ltd.·interventional·Posted Mar 15, 2018·Updated Oct 9, 2024

In Brief

A Phase 1 clinical trial evaluating Gumarontinib Tablets for Advanced Solid Tumor. Completed, enrolled 56 participants across 1 site.

Detailed Summary

This study evaluates the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of SCC244 in patients with advanced solid tumors with c-Met Alterations.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Solid Tumor
CountriesChina
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMar 15, 2018
Enrollment StartSep 14, 2017
Primary CompletionJan 9, 2023
TodayJul 1, 2026
Enrollment to primary: 5.3 yearsPosted 8.3 years ago

Interventions

Gumarontinib Tabletsdrug

Either at 100mgSD、100mgQD、200mgSD、200mgQD、400mgSD、400mgQD、300mgBID、400mgBID